Sbi Pharmaceuticals Co., Ltd.

Osaka City University

Urara Ota

Masahiro Ishizuka

Tohru Tanaka

Kiwamu Takahashi

Motowo Nakajima

Fuminori Abe

Keitaro Watanabe

Toshiyuki Ozawa

Mika Morishita

Atsuko Kamiya

Kuniyuki Morimoto

The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.

Aqueous formulation containing 5-aminolevulinic acid or the like

It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.

Diagnostic agent for tumor

Growing community of inventors

Hyogo, Japan

Urara Ota